Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
US6458779B1 · kind B1 · utility
1Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2001 |
| Grant date | Oct 1, 2002 |
| Priority date | — |
| Expiry date | Apr 5, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of Formula (1) wherein: R is methyl substituted by one to three groups from alkyl, aryl, alkenyl, and alkynyl; n is ) or 1; R1 is arylmethyl or heterocyclylmethyl; R2 is alkyl, alkenyl, cycloalkyl or cycloalkenyl; and R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated y s-CD23.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.